Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

MORRISTOWN, N.J., Sept. 26, 2025 /PRNewswire/ -- Sanofi US today announces a broad expansion of its Insulins Valyou Savings Program by offering a 30-day supply of any Sanofi insulin for $35 to all patients in the US with a valid prescription. The program, first created for people without health insurance, will be available to all Americans regardless of insurance status, including those with commercial insurance or Medicare, to ensure affordable access to these critical medicines.

Sanofi's expanded Insulins Valyou Savings Program now ensures no American needs to pay more than $35 per month for their Sanofi insulins.

"Our announcement builds on an idea first championed by President Trump to lower costs for American patients at the pharmacy counter. At Sanofi, we share his objective and believe that no one should struggle to afford their insulin and we are proud to take this next step as we play our part to keep America healthy," said Adam Gluck, Head of US Corporate Affairs, Sanofi. "By expanding our Insulins Valyou Savings Program, we're taking concrete action to address a critical healthcare issue for millions of Americans living with diabetes. We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines."

Sanofi's Insulins Valyou Savings Program works at most pharmacies across the US, including independent and rural pharmacies, without creating complex hurdles for patients.

The expanded program will cover all Sanofi insulins and will be implemented nationwide. This initiative builds on Sanofi's longstanding commitment to access and affordability. Under this expansion, every American will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for a fixed monthly price of $35.

"Diabetes management requires consistent access to medication, and financial barriers can lead to rationing or skipping doses, which can have serious health consequences," said Olivier Bogillot, Head of General Medicines, North America, Sanofi. "This program expansion emphasizes our continued support for America's diabetes community."

The expanded Insulins Valyou Savings Program will be available to patients beginning January 1, 2026. Patients can enroll at Sanofi Patient Connection or by calling 1-888-847-4877.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]

Investor Relations
Thomas Kudsk Larsen |+44 7545 513 693 | [email protected]
Alizé Kaisserian | +33 6 47 04 12 11 | [email protected]
Felix Lauscher | +1 908 612 7239 | [email protected]
Keita Browne | +1 781 249 1766 | [email protected]
Nathalie Pham | +33 7 85 93 30 17 | [email protected]
Tarik Elgoutni | +1 617 710 3587 | [email protected]
Thibaud Châtelet | +33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.

SOURCE Sanofi